[1]
Chapman TM, Perry CM. Cefepime: a review of its use in the management of hospitalized patients with pneumonia. American journal of respiratory medicine : drugs, devices, and other interventions. 2003:2(1):75-107
[PubMed PMID: 14720024]
[2]
Rivera CG, Narayanan PP, Patel R, Estes LL. Impact of Cefepime Susceptible-Dose-Dependent MIC for Enterobacteriaceae on Reporting and Prescribing. Antimicrobial agents and chemotherapy. 2016 Jun:60(6):3854-5. doi: 10.1128/AAC.00442-16. Epub 2016 May 23
[PubMed PMID: 27067319]
[3]
Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2022 Aug 25:75(2):187-212. doi: 10.1093/cid/ciac268. Epub
[PubMed PMID: 35439291]
[4]
Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2022 Jul 6:74(12):2089-2114. doi: 10.1093/cid/ciab1013. Epub
[PubMed PMID: 34864936]
[5]
Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston K, Strasfeld L, Flowers CR. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 May 10:36(14):1443-1453. doi: 10.1200/JCO.2017.77.6211. Epub 2018 Feb 20
[PubMed PMID: 29461916]
Level 1 (high-level) evidence
[6]
Nguyen HM, Shier KL, Graber CJ. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. The Journal of antimicrobial chemotherapy. 2014 Apr:69(4):871-80. doi: 10.1093/jac/dkt450. Epub 2013 Nov 20
[PubMed PMID: 24265230]
[7]
Patel HB, Lusk KA, Cota JM. The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections. Journal of pharmacy practice. 2019 Aug:32(4):458-463. doi: 10.1177/0897190017743134. Epub 2017 Nov 22
[PubMed PMID: 29166830]
[8]
Walker KJ, Lee YR, Klar AR. Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems. The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale. 2018:2018():3747521. doi: 10.1155/2018/3747521. Epub 2018 Feb 8
[PubMed PMID: 29670677]
Level 2 (mid-level) evidence
[9]
Endimiani A, Perez F, Bonomo RA. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert review of anti-infective therapy. 2008 Dec:6(6):805-24. doi: 10.1586/14787210.6.6.805. Epub
[PubMed PMID: 19053894]
[10]
Kessler RE. Cefepime microbiologic profile and update. The Pediatric infectious disease journal. 2001 Mar:20(3):331-6
[PubMed PMID: 11303846]
[11]
Winter MA, Guhr KN, Berg GM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacotherapy. 2012 Jul:32(7):604-12. doi: 10.1002/j.1875-9114.2012.01098.x. Epub 2012 May 10
[PubMed PMID: 22576791]
[12]
Bauer KA, West JE, O'Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrobial agents and chemotherapy. 2013 Jul:57(7):2907-12. doi: 10.1128/AAC.02365-12. Epub 2013 Apr 9
[PubMed PMID: 23571547]
[13]
Wrenn RH, Cluck D, Kennedy L, Ohl C, Williamson JC. Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2018 Apr:24(3):170-175. doi: 10.1177/1078155216687151. Epub 2017 Jan 11
[PubMed PMID: 28077047]
[14]
Zhu LL, Zhou Q. Optimal infusion rate in antimicrobial therapy explosion of evidence in the last five years. Infection and drug resistance. 2018:11():1105-1117. doi: 10.2147/IDR.S167616. Epub 2018 Aug 8
[PubMed PMID: 30127628]
[15]
Li L, Li X, Xia Y, Chu Y, Zhong H, Li J, Liang P, Bu Y, Zhao R, Liao Y, Yang P, Lu X, Jiang S. Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy. Frontiers in pharmacology. 2020:11():786. doi: 10.3389/fphar.2020.00786. Epub 2020 May 29
[PubMed PMID: 32547394]
[16]
Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery. Obstetrics and gynecology. 2018 Sep:132(3):e103-e119. doi: 10.1097/AOG.0000000000002833. Epub
[PubMed PMID: 30134425]
[18]
Arnold CJ, Ericson J, Cho N, Tian J, Wilson S, Chu VH, Hornik CP, Clark RH, Benjamin DK Jr, Smith PB, Best Pharmaceuticals for Children Act--Pediatric Trials Network Administrative Core Committee. Cefepime and Ceftazidime Safety in Hospitalized Infants. The Pediatric infectious disease journal. 2015 Sep:34(9):964-8. doi: 10.1097/INF.0000000000000778. Epub
[PubMed PMID: 26376308]
[19]
de Cacqueray N, Hirt D, Zheng Y, Bille E, Leger PL, Rambaud J, Toubiana J, Chosidow A, Vimont S, Callot D, Chouchana L, Béranger A, Tréluyer JM, Benaboud S, Oualha M. Cefepime population pharmacokinetics and dosing regimen optimization in critically ill children with different renal function. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2022 Oct:28(10):1389.e1-1389.e7. doi: 10.1016/j.cmi.2022.05.007. Epub 2022 May 20
[PubMed PMID: 35605841]
[20]
Saini T, Gaines MN, Sohal A, Li L. Cefepime-Induced Neurotoxicity. Cureus. 2021 Sep:13(9):e17831. doi: 10.7759/cureus.17831. Epub 2021 Sep 8
[PubMed PMID: 34660040]
[21]
Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, Fraser GL. Cefepime-induced neurotoxicity: a systematic review. Critical care (London, England). 2017 Nov 14:21(1):276. doi: 10.1186/s13054-017-1856-1. Epub 2017 Nov 14
[PubMed PMID: 29137682]
Level 1 (high-level) evidence
[22]
Deshayes S, Coquerel A, Verdon R. Neurological Adverse Effects Attributable to β-Lactam Antibiotics: A Literature Review. Drug safety. 2017 Dec:40(12):1171-1198. doi: 10.1007/s40264-017-0578-2. Epub
[PubMed PMID: 28755095]
[23]
Huwyler T, Lenggenhager L, Abbas M, Ing Lorenzini K, Hughes S, Huttner B, Karmime A, Uçkay I, von Dach E, Lescuyer P, Harbarth S, Huttner A. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2017 Jul:23(7):454-459. doi: 10.1016/j.cmi.2017.01.005. Epub 2017 Jan 19
[PubMed PMID: 28111294]
Level 2 (mid-level) evidence
[24]
Isitan C, Ferree A, Hohler AD. Cefepime induced neurotoxicity: A case series and review of the literature. eNeurologicalSci. 2017 Sep:8():40-43. doi: 10.1016/j.ensci.2017.08.001. Epub 2017 Aug 4
[PubMed PMID: 29260037]
Level 2 (mid-level) evidence
[25]
Appa AA, Jain R, Rakita RM, Hakimian S, Pottinger PS. Characterizing Cefepime Neurotoxicity: A Systematic Review. Open forum infectious diseases. 2017 Fall:4(4):ofx170. doi: 10.1093/ofid/ofx170. Epub 2017 Oct 10
[PubMed PMID: 29071284]
Level 1 (high-level) evidence
[26]
Alhassani RY, Bagadood RM, Balubaid RN, Barno HI, Alahmadi MO, Ayoub NA. Drug Therapies Affecting Renal Function: An Overview. Cureus. 2021 Nov:13(11):e19924. doi: 10.7759/cureus.19924. Epub 2021 Nov 26
[PubMed PMID: 34976524]
Level 3 (low-level) evidence
[27]
Pak S, Kim SY, Kim SH, Joung JY, Park WS, Chung J, Lee KH, Seo HK. Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer. Frontiers in oncology. 2021:11():570077. doi: 10.3389/fonc.2021.570077. Epub 2021 Apr 2
[PubMed PMID: 33868985]
[28]
Jackson BR,Iqbal S,Mahon B,Centers for Disease Control and Prevention (CDC)., Updated recommendations for the use of typhoid vaccine--Advisory Committee on Immunization Practices, United States, 2015. MMWR. Morbidity and mortality weekly report. 2015 Mar 27
[PubMed PMID: 25811680]
[29]
Vorobeichik L, Weber EA, Tarshis J. Misconceptions Surrounding Penicillin Allergy: Implications for Anesthesiologists. Anesthesia and analgesia. 2018 Sep:127(3):642-649. doi: 10.1213/ANE.0000000000003419. Epub
[PubMed PMID: 29757781]
[30]
Pichichero ME, Zagursky R. Penicillin and cephalosporin allergy. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2014 May:112(5):404-12. doi: 10.1016/j.anai.2014.02.005. Epub
[PubMed PMID: 24767695]
[31]
Mine Y, Nishida M, Goto S, Kuwahara S. Cefazolin, a new semisynthetic cephalosporin antibiotic. IV. Antigenicity of cefazolin and its cross reactivity with benzylpenicillin, ampicillin and cephaloridine. The Journal of antibiotics. 1970 Apr:23(4):195-203
[PubMed PMID: 5429508]
[32]
Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2010 Oct:105(4):259-273. doi: 10.1016/j.anai.2010.08.002. Epub
[PubMed PMID: 20934625]
[33]
Shah K, Pass LA, Cox M, Lanham M, Arnold FW. Evaluating contemporary antibiotics as a risk factor for Clostridium difficile infection in surgical trauma patients. The journal of trauma and acute care surgery. 2012 Mar:72(3):691-5. doi: 10.1097/TA.0b013e31823c5637. Epub
[PubMed PMID: 22491554]
[34]
Durand-Maugard C, Lemaire-Hurtel AS, Gras-Champel V, Hary L, Maizel J, Prud'homme-Bernardy A, Andréjak C, Andréjak M. Blood and CSF monitoring of cefepime-induced neurotoxicity: nine case reports. The Journal of antimicrobial chemotherapy. 2012 May:67(5):1297-9. doi: 10.1093/jac/dks012. Epub 2012 Jan 31
[PubMed PMID: 22298349]
Level 3 (low-level) evidence
[35]
Lamoth F, Buclin T, Pascual A, Vora S, Bolay S, Decosterd LA, Calandra T, Marchetti O. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrobial agents and chemotherapy. 2010 Oct:54(10):4360-7. doi: 10.1128/AAC.01595-08. Epub 2010 Jul 12
[PubMed PMID: 20625153]
[36]
Chapuis TM, Giannoni E, Majcherczyk PA, Chioléro R, Schaller MD, Berger MM, Bolay S, Décosterd LA, Bugnon D, Moreillon P. Prospective monitoring of cefepime in intensive care unit adult patients. Critical care (London, England). 2010:14(2):R51. doi: 10.1186/cc8941. Epub 2010 Apr 1
[PubMed PMID: 20359352]
[37]
Ortega AJ, Ghafouri SR, Vu L, Edwards B, Nickel N. Cefepime-Induced Encephalopathy in a High-Risk Patient With Renal Insufficiency and Cirrhosis. Cureus. 2021 Oct:13(10):e18767. doi: 10.7759/cureus.18767. Epub 2021 Oct 14
[PubMed PMID: 34796060]
[38]
Baillargeon J, Holmes HM, Lin YL, Raji MA, Sharma G, Kuo YF. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. The American journal of medicine. 2012 Feb:125(2):183-9. doi: 10.1016/j.amjmed.2011.08.014. Epub
[PubMed PMID: 22269622]